Compound monograph
Degarelix
Degarelix is a synthetic linear decapeptide with an acetylated N terminus, an amidated C terminus and explicitly configured nonstandard residues. This record describes the parent without acetate or hydrate components.
01
Identity & nomenclature
Degarelix is a synthetic linear decapeptide with an acetylated N terminus, an amidated C terminus and explicitly configured nonstandard residues. This record describes the parent without acetate or hydrate components.
Degarelixum is the issued Latin name. The parent identifiers exclude the distinct acetate and hydrated acetate registry representations. No fixed acetate or water stoichiometry is assigned to all preparations bearing a salt-qualified name.
Declared aliases and development codes: Degarelixum.
02
Molecular properties
| Molecular formula | C82H103ClN18O16 |
|---|---|
| Molecular mass | 1632.286 Da |
| CAS Registry Number | 214766-78-6 |
| PubChem CID | 16136245 |
| UNII | SX0XJI3A11 |
| Three-letter sequence | D-2Nal–D-4Cpa–D-3Pal–Ser–4Aph(L-Hor)–D-4Aph(Cbm)–Leu–Lys(iPr)–Pro–D-Ala |
| Terminal groups | N-terminal acetylation; C-terminal amide |
D-2Nal is D-3-(naphthalen-2-yl)alanine; D-4Cpa is D-4-chlorophenylalanine; D-3Pal is D-3-(pyridin-3-yl)alanine. 4Aph(L-Hor) is L-4-aminophenylalanine with its para amino group acylated by L-hydroorotic acid, whose additional stereocentre is 4S. D-4Aph(Cbm) is D-4-aminophenylalanine with a para carbamoylated amino group. Lys(iPr) is N6-isopropyl-L-lysine. Positions 1, 2, 3, 6 and 10 are D; positions 4, 5, 7, 8 and 9 are L. Each token is one residue; no one-letter string is supplied.
03
Structural characteristics
Takahashi, Inomata and Fukui reported independent peptide synthesis with chromatographic product characterization. That evidence does not independently establish all stereocentres. The stated parent has eleven specified stereocentres, including the residue-5 side-chain centre. The proline and hydroorotyl rings are within their units; neither is an inter-residue closure.
- D configuration at residues 1, 2, 3, 6 and 10
- Residue-5 para-amino acylation with L-hydroorotyl, including its 4S stereocentre
- Residue-6 para-amino carbamoylation
- Residue-8 N6-isopropyl substitution
Terminal features: N-terminal acetylation, C-terminal amide.
04
Molecular targets & mechanisms
05
Analytical considerations
The formula and 1632.286 Da average mass follow the parent structure using CIAAW 2024 abridged atomic weights. The neutral monoisotopic calculation is a different mass convention. Counterion, hydrate, isotope-labelled and conjugated compositions are not transferred to the parent.
What the studies reported
No verified findings are published for this record under Content Policy v1.
06
Verified bibliography
Cited studies by type
The one paper this record cites, counted by the kind of work each reports. A count is the size of this record's selection, not of the research that exists, and says nothing about results, safety, effectiveness or approval.
A paper can report more than one kind of work. Each count opens those papers in the bibliography. Compare every record on the Evidence Map.
Reference 1
AJIPHASE®: A Highly Efficient Synthetic Method for One-Pot Peptide Elongation in the Solution Phase by an Fmoc Strategy.Takahashi D, Inomata T, Fukui T
Angewandte Chemie (International ed. in English) · 2017-06-07 · Journal Article
current
Study models of these references
What kind of experiment each cited paper reports, taken from its abstract unless marked. Not a summary of results.
| Reference | Study models |
|---|---|
| Takahashi D et al. 2017 | Chemical, structural or analytical study; no biological model reported |
Record history
Published 2026-10-20.
No changes to this record's content have been recorded since publication.
Each entry names the parts of this record that changed on that date. Changes to links between records and to catalogue links are not listed. This history covers the tracked record fields; study findings are not listed here.
Cite this record: Purely Peptides Research Library. Degarelix. Published 2026-10-20. https://purelypeptides.org/research/compounds/degarelix/
10
Methodology & citation verification
Reference identity is checked against official PubMed metadata. Local deterministic receipts bind each normalized title and canonical metadata record to its verification date. Scientific values remain absent when an authoritative source has not been verified.
Read the full methodology →